RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Cue Biopharma EBIT 2024

Cue Biopharma EBIT

-57.46 M USD

Cue Biopharma Dividend yield

Ticker

CUE

ISIN

US22978P1066

WKN

A2JAT5

In 2024, Cue Biopharma's EBIT was -57.46 M USD, a 10.51% increase from the -51.99 M USD EBIT recorded in the previous year.

The Cue Biopharma EBIT history

YEAREBIT (undefined USD)
2030e294.57
2029e203.59
2028e-32.22
2027e-61.06
2026e-85.26
2025e-71.54
2024e-57.46
2023-51.99
2022-53.5
2021-43.71
2020-45.04
2019-36.77
2018-38.7
2017-23.23
2016-7.66
2015-1.93

Cue Biopharma Aktienanalyse

What does Cue Biopharma do?

Cue Biopharma Inc is a biotechnology company focused on the development of novel immune-competent molecules for cancer therapy and immune system strengthening. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. The history of Cue Biopharma Inc began with the founding of the company by three leading scientists who combined their expertise in biology, chemistry, and drug design to develop novel and effective cancer immunotherapies. The company aimed to develop these new therapies with the precision of molecular interactions that are crucial for immune system control. Cue Biopharma Inc has a unique business model based on its proprietary CueMol technology platform, which enables the company to gain insightful understanding of molecular interactions in the immune system. By combining bioinformatics, artificial intelligence, and experimental technologies, CueMol is able to model the complex interplay of proteins, cells, and tissues in the immune system. The various divisions of Cue Biopharma Inc can be divided into three main areas: oncology, autoimmune diseases, and infectious diseases. In the field of oncology, the company has a pipeline of products including CB-010, CB-020, and CB-030, targeting different types of tumors. These therapeutics work by blocking protein-protein interactions that enable cancer cells to escape immune surveillance, thus improving the ability of the immune system to recognize and fight the tumor. In the field of autoimmune diseases, Cue Biopharma Inc has made significant progress in the development of CB-110, a therapeutic for the treatment of lupus. CB-110 works by regulating T cells, leading to a reduction in the inflammation that causes lupus symptoms. In the field of infectious diseases, Cue Biopharma Inc has played a valuable role in the development of COVID-19 therapeutics. In 2020, the company began developing CB-001, a drug targeting the SARS-CoV-2 virus. CueMol enabled the company to quickly understand the molecular interactions of the virus and develop CB-001 by disrupting these interactions. Cue Biopharma Inc has entered into several partnerships with leading pharmaceutical companies. In 2019, the company collaborated with Merck & Co. to further develop its CueMol platform and develop novel cancer immunotherapies. In 2020, the company worked with the Sheba Medical Center to test the efficacy of CB-001 in COVID-19 patients. Overall, Cue Biopharma Inc is a promising biotechnology company with the ability to develop novel immunotherapeutic drugs for the treatment of cancer, autoimmune diseases, and infectious diseases through the use of innovative technologies such as CueMol. With its partnerships, pipeline of therapeutics, and advanced technologies, Cue Biopharma Inc is poised to play a significant role in the biotechnology industry in the coming years. Cue Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Cue Biopharma's EBIT

Cue Biopharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Cue Biopharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Cue Biopharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Cue Biopharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Cue Biopharma Stock

How much did Cue Biopharma achieve in EBIT for the current year?

In the current year, Cue Biopharma has achieved an EBIT of -57.46 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Cue Biopharma.

How has the EBIT of Cue Biopharma developed in recent years?

The EBIT of Cue Biopharma has increased by 10.511% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Cue Biopharma?

The EBIT of Cue Biopharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Cue Biopharma pay?

Over the past 12 months, Cue Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cue Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Cue Biopharma?

The current dividend yield of Cue Biopharma is .

When does Cue Biopharma pay dividends?

Cue Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cue Biopharma?

Cue Biopharma paid dividends every year for the past 0 years.

What is the dividend of Cue Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cue Biopharma located?

Cue Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cue Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cue Biopharma from 5/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/20/2024.

When did Cue Biopharma pay the last dividend?

The last dividend was paid out on 5/20/2024.

What was the dividend of Cue Biopharma in the year 2023?

In the year 2023, Cue Biopharma distributed 0 USD as dividends.

In which currency does Cue Biopharma pay out the dividend?

The dividends of Cue Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Cue Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Cue Biopharma

Our stock analysis for Cue Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cue Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.